Description

[5-(4-Bromophenyl)-3-Methylisoxazol-4-Yl]Carbamic Acid(R)-1-Phenylethyl Ester is a high-purity, advanced pharmaceutical intermediate characterized by its chiral center and complex heterocyclic structure. This compound matters for its critical role as a building block in the synthesis of novel active pharmaceutical ingredients (APIs), particularly those targeting specific biological pathways. Pharmaceutical R&D teams and fine chemical manufacturers need it to develop and scale up production of new therapeutic agents, leveraging its defined stereochemistry for precise molecular construction.

Application

• Pharmaceutical Intermediate: A key chiral building block in the research and development of new drug candidates, particularly in oncology and central nervous system (CNS) therapeutic areas.
• Active Pharmaceutical Ingredient (API) Synthesis: Used in the multi-step synthesis of complex target molecules where the isoxazole and bromophenyl motifs are required pharmacophores.
• Chemical Biology Research: Serves as a probe or precursor in medicinal chemistry for structure-activity relationship (SAR) studies and hit-to-lead optimization.
• Process Chemistry & Scale-Up: Employed in pilot plant and commercial-scale manufacturing processes for APIs under current Good Manufacturing Practice (cGMP) standards.
• Contract Research & Manufacturing (CRAM): Supplied to organizations specializing in custom synthesis and development services for the global pharmaceutical industry.

Basic Information

Product Name	[5-(4-Bromophenyl)-3-Methylisoxazol-4-Yl]Carbamic Acid(R)-1-Phenylethyl Ester
CAS No.	1228690-37-6
Molecular Formula	C19H17BrN2O3
Molecular Weight	401.26 g/mol
Synonyms	(R)-1-Phenylethyl [5-(4-bromophenyl)-3-methyl-4-isoxazolyl]carbamate; Carbamic acid, N-[5-(4-bromophenyl)-3-methyl-4-isoxazolyl]-, (1R)-1-phenylethyl ester; (R)-1-Phenylethyl 5-(4-bromophenyl)-3-methylisoxazole-4-carboxylate (common naming variant); (1R)-1-Phenylethyl 5-(4-bromophenyl)-3-methyl-1,2-oxazole-4-carboxylate; BPI-Carbamate-(R)-Ester; 1228690-37-6; 4-Isoxazolecarbamic acid derivative
EINECS	Contact for details

Quality Control

Every batch of [5-(4-Bromophenyl)-3-Methylisoxazol-4-Yl]Carbamic Acid(R)-1-Phenylethyl Ester is manufactured and tested under a rigorous quality management system. We provide comprehensive analytical data to ensure identity, purity, and chiral integrity, meeting the exacting standards required for pharmaceutical development. A Certificate of Analysis (COA) detailing specifications such as assay (HPLC), chiral purity, and related substances is supplied with each shipment. Our cGMP-compliant processes ensure traceability and consistency for critical applications.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (typically 15-25°C). This compound may be light-sensitive and/or hygroscopic; handling under an inert atmosphere is recommended for long-term storage to maintain stability and purity. Keep away from strong oxidizing agents.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥98.0%
Chiral Purity (Chiral HPLC)	≥99.0% (R-isomer)
Related Substances (HPLC)	Total impurities ≤2.0%
Any single unknown impurity	≤0.5%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Heavy Metals	≤20 ppm
Loss on Drying	≤0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.